NEW YORK (GenomeWeb) – NanoString Technologies and Sysmex subsidiary Riken Genesis said today that they have entered into a partnership to bring nCounter-based diagnostic assays to the Japanese market. 

Under the agreement, NanoString and Riken will collaborate to commercialize, register, and gain reimbursement for companion diagnostic tests, including a lymphoma subtyping test that  will be marketed as the nCounter Dx LymphMark assay.